$88 Million: Medical Company Reports Promising Skin Disorder Treatment

VYNE Therapeutics Achieves Promising Phase 1b Trial Results for BET Inhibitor VYN201, Revealing Hope for Nonsegmental Vitiligo Patients.

VYNE Therapeutics, a leading pharmaceutical company, has recently reported positive data from its Phase 1b clinical trial for its novel Bromodomain and Extra-Terminal motif (BET) inhibitor, VYN201. The clinical trial was focused on patients suffering from nonsegmental vitiligo, a chronic skin disorder that results in the loss of skin color in blotches.

https://stockregion.app/p/88-million-medical-company-reports